Relmada Therapeutics (RLMD) Other Accumulated Expenses (2019 - 2026)
Relmada Therapeutics (RLMD) reported Other Accumulated Expenses of $76100.0 for Q1 2026, up 12.57% year-over-year from $67600.0 in Q1 2025, and down 43.38% quarter-over-quarter from $134400.0 in Q4 2025.
Relmada Therapeutics (RLMD) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 6 years of Other Accumulated Expenses data on file, last reported at $76100.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $76100.0, up 12.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $76100.0 (up 12.57% YoY), and the FY2025 annual result was $134400.0, up 3.86% from the prior year.
- Other Accumulated Expenses declined to $76100.0 in Q1 2026 per RLMD's latest filing, from $134400.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $134400.0 in Q4 2025 and troughed at $67600.0 in Q1 2025.
- A 4-year average of $95450.0 and a median of $80600.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses increased 0.75% in 2025, then climbed 12.57% in 2026.
- A 4-year view of Other Accumulated Expenses shows it stood at $115500.0 in 2023, then rose by 12.03% to $129400.0 in 2024, then climbed by 3.86% to $134400.0 in 2025, then slumped by 43.38% to $76100.0 in 2026.
- Business Quant data shows RLMD's Other Accumulated Expenses at $76100.0 in Q1 2026, $134400.0 in Q4 2025, and $80900.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76,100.00 |
| Dec 31, 2025 | 134,400.00 |
| Sep 30, 2025 | 80,900.00 |
| Jun 30, 2025 | 79,400.00 |
| Mar 31, 2025 | 67,600.00 |
| Dec 31, 2024 | 129,400.00 |
| Sep 30, 2024 | 80,300.00 |
| Dec 31, 2023 | 115,500.00 |
| Dec 31, 2020 | 126,200.00 |
| Jun 30, 2020 | 65,900.00 |
| Dec 31, 2019 | 92,900.00 |
| Sep 30, 2019 | 65,200.00 |
| Jun 30, 2019 | 59,400.00 |